701 related articles for article (PubMed ID: 27530322)
1. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
[TBL] [Abstract][Full Text] [Related]
2. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
3. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
4. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
[TBL] [Abstract][Full Text] [Related]
5. C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation.
Chiang Y; Lu LF; Tsai CL; Tsai YC; Wang CC; Hsueh FJ; Huang CY; Chen CH; Pu YS; Cheng JC
Eur J Cancer; 2024 Feb; 198():113521. PubMed ID: 38171115
[TBL] [Abstract][Full Text] [Related]
6. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
[TBL] [Abstract][Full Text] [Related]
7. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma.
Brandenburg S; Turkowski K; Mueller A; Radev YT; Seidlitz S; Vajkoczy P
Immunol Res; 2017 Jun; 65(3):757-768. PubMed ID: 28367602
[TBL] [Abstract][Full Text] [Related]
9. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.
Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R
Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177
[TBL] [Abstract][Full Text] [Related]
10. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.
Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS
Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615
[TBL] [Abstract][Full Text] [Related]
11. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
12. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
[TBL] [Abstract][Full Text] [Related]
13. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.
Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M
Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799
[TBL] [Abstract][Full Text] [Related]
14. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.
Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897
[TBL] [Abstract][Full Text] [Related]
15. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
16. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF
Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019
[TBL] [Abstract][Full Text] [Related]
17. Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment.
Oo MW; Kawai H; Takabatake K; Tomida S; Eguchi T; Ono K; Shan Q; Ohara T; Yoshida S; Omori H; Sukegawa S; Nakano K; Okamoto K; Sasaki A; Nagatsuka H
JCI Insight; 2022 Jan; 7(1):. PubMed ID: 34874922
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions.
Liu J; Piranlioglu R; Ye F; Shu K; Lei T; Nakashima H
Front Cell Infect Microbiol; 2023; 13():1141034. PubMed ID: 37234776
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells accumulate among myeloid cells contributing to tumor growth in matrix metalloproteinase 12 knockout mice.
Li J; Zhang X; Liu Q; Yang M; Zhou Z; Ye Y; Zhou Z; He X; Wang L
Cell Immunol; 2018 May; 327():1-12. PubMed ID: 29555056
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
